Tagged Articles

AndroGel 179 articles

Fewer men using testosterone therapy following FDA warnings

Fewer men in the United States are using testosterone replacement therapy following a stark decrease from 2013 to 2016 over concerns with over-prescribing and health risks, according to researchers with the University of Texas Medical Branch at Galveston. Testosterone treatments, including AbbVie’s Androgel, were heavily touted by drug companies as cure-alls for so-called Low T, a contrived condition caused by an age-related drop in testosterone levels that leads to symptoms such as low sex drive, weight gain, muscle loss and fatigue. The ad campaign resulted in hundreds of thousands of prescriptions for the male hormone supplement. Testosterone replacement therapies are ... Read More

AbbVie testosterone case to be retried

An Illinois federal judge has ordered a retrial of the second bellwether in a multidistrict litigation alleging testosterone replacement therapy makers failed to warn about cardiovascular risks with their products. In October, plaintiff Jeffrey Konrad was awarded $140,000 in compensatory damages and $140 million in punitive damages after he blamed AbbVie’s AndroGel for causing his heart attack. But U.S. District Judge Matthew Kennelly found that the jury’s finding of strict liability clashed with Konrad’s negligence claim. At issue is the instructions given to the jury for strict liability and negligence claims, both of which required the jury to find that ... Read More

Actavis poised to settle testosterone side effects lawsuits

Actavis Inc., a pharmaceutical company named in a multidistrict litigation (MDL) alleging failure to warn of cardiovascular risks with testosterone replacement therapies, has reached a memorandum of understanding on a potential global settlement concerning its testosterone treatment Androderm. Actavis is the latest testosterone manufacturer to make a move toward exiting the MDL, following similar measures by Auxilium Pharmaceuticals LLC, Eli Lilly & Co., Endo Pharmaceuticals PLC, and GlaxoSmithKline LLC. AbbVie is the only drug company in the MDL that has yet to make an effort to resolve outstanding cases. The AndroGel manufacturer also faces the most lawsuits in the litigation. ... Read More

AbbVie, Besins fined for delaying generic versions of AndroGel

AbbVie Inc., and its affiliate Bensons Healthcare were ordered to pay $448 million for allegedly reaping more than $1 billion in profits after filing sham lawsuits to keep competitors from launching generic versions of the companies’ top selling testosterone replacement therapy AndroGel. The companies filed patent lawsuits against Teva Pharmaceuticals USA and Perrigo Co., which were later ruled baseless by U.S. District Judge Harvey Bartle. If not for AbbVie and Besins’ efforts, Perrigo could have entered the market in June 2013 with its own generic version of AndroGel. “The patent attorneys also clearly recognized that the entry of generic versions ... Read More

AbbVie accused of misusing plaintiff profile forms in testosterone MDL

Attorneys representing consumers in a multidistrict litigation (MDL) accusing testosterone treatment manufacturers of failing to warn that their products carried cardiovascular risks asked an Illinois federal judge to fine AbbVie Inc., nearly a half million dollars for misusing a records-collecting process to challenge almost 1,000 cases. The plaintiffs’ attorneys told U.S. District Judge Matthew Kennelly that AbbVie, maker of the top-selling AndroGel testosterone replacement therapy, was improperly using the plaintiff profile forms in an attempt to have the cases dismissed. As a result, the plaintiffs’ steering committee has spent tremendous time and effort to respond to the drug company’s issues. ... Read More

AbbVie faces more lawsuits in testosterone MDL

AbbVie Inc., prevailed in the latest bellwether trial accusing the company’s testosterone treatment AndroGel of causing heart attacks, strokes and blood clots, but AbbVie and other testosterone manufacturers still face thousands more lawsuits consolidated in a multidistrict litigation in the U.S. District Court for the Northern District of Illinois. This is the third of five bellwether trials that have been won by testosterone makers. The other two have resulted in a total of $143 million in verdicts for the plaintiffs. The latest trial involved the case of Rober Rowley who was prescribed AndroGel in 2012 to treat fatigue. Years earlier, ... Read More

AbbVie ignored heart risks with AndroGel, lawyer claims

AbbVie Inc., turned a blind eye on cardiovascular risks associated with its AndroGel testosterone replacement therapy, said the attorney for a man suing the company over claims that AndroGel caused a blood clot to develop deep in his veins. The only warning Robert Rowley had that his testosterone treatment could cause heart attacks, strokes and blood clots was a warning on the product’s safety label about an increased risk for polycythemia, a blood thickening disease that can lead to blood clots. “But it’s not the only way,” Rowley’s attorney told an Illinois federal jury during the latest bellwether trial in ... Read More

Besins released from testosterone MDL

Thailand-based Besins Healthcare SA, which manufactures the topical testosterone treatment AndroGel outside the United States, was released from a multidistrict litigation (MDL) involving several manufacturers of testosterone replacement therapies. Besins licensed exclusive right to market and distribute AndroGel in the U.S. to AbbVie. U.S. District Judge Matthew F. Kennelly dismissed all remaining claims against Besins after finding that plaintiffs did not allege that the company had a responsibility to conduct safety tests of AndroGel in the U.S. AbbVie and other testosterone makers are facing about 6,500 of claims in a multidistrict litigation centralized in the Northern District of Illinois. Most ... Read More

Verdict reached in latest testosterone side effects trial

Jurors in the fifth bellwether to be tried a multi district litigation (MDL) accusing testosterone replacement therapies of causing serious cardiovascular events found in favor of the defense. More than 6,500 cases remain in the MDL against testosterone makers, where previous verdicts have resulted in multimillion dollar awards to victims of testosterone side effects. Arthur Myers and his wife Heather sued AbbVie Inc., in 2015, claiming Arthur was lured to seek specific testing and treatment for low testosterone by the drug company’s direct-to-consumer advertising for its top-selling testosterone treatment AndroGel. In February 2008, Arthur suffered a pulmonary embolism, or blood ... Read More

AbbVie fights to reduce or overturn $3.2 million verdict

A month after an Illinois federal jury awarded a man $3.2 million over claims AbbVie Inc.’s testosterone replacement therapy AndroGel gave him a heart attack, the drug company asked the federal court to overturn the verdict or at the very least grant a new trial, arguing the jury’s finding that the company was negligent was inconsistent with its finding against strict liability and fraudulent misrepresentation. Plaintiff Jesse Mitchell sued AbbVie alleging that studies linked use of testosterone replacement therapies to an increased risk of heart attacks, strokes and blood clots, but the company failed to adequately warn doctors or patients ... Read More